Clinical pharmacology of moxalactam in patients with malignant disease.

Pharmacological studies of moxalactam were conducted with 37 cancer patients. Intramuscular administration of 500 mg of moxalactam to 10 patients produced a mean peak serum concentration of 12.4 micrograms/ml. The serum terminal-phase half-life was 3.9 h. Intravenous administration of 500 mg of moxa...

Ausführliche Beschreibung

Bibliografische Detailangaben

Veröffentlicht in:	Antimicrob Agents Chemother
Hauptverfasser:	Estey, E H, Weaver, S S, Ho, D H, Bodey, G P
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	American Society for Microbiology (ASM) 1981
Schlagworte:	Research Article
Online-Zugang:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC181493/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/6454389/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.19.4.639
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!